182 related articles for article (PubMed ID: 33880019)
1. Effect of SGRQ-Defined Chronic Bronchitis at Baseline on Treatment Outcomes in Patients with COPD Receiving Nebulized Glycopyrrolate.
Tashkin DP; Ozol-Godfrey A; Sharma S; Sanjar S
Int J Chron Obstruct Pulmon Dis; 2021; 16():945-955. PubMed ID: 33880019
[TBL] [Abstract][Full Text] [Related]
2. Effect of Gender on Lung Function and Patient-Reported Outcomes in Patients with COPD Receiving Nebulized Glycopyrrolate.
Ohar JA; Ozol-Godfrey A; Goodin T; Sanjar S
Int J Chron Obstruct Pulmon Dis; 2020; 15():995-1004. PubMed ID: 32440111
[TBL] [Abstract][Full Text] [Related]
3. Improvement in Lung Function and Patient-Reported Outcomes in Patients with COPD with Comorbid Anxiety and Depression Receiving Nebulized Glycopyrrolate in the GOLDEN 3 and 4 Studies.
Hanania NA; Yohannes AM; Ozol-Godfrey A; Tocco M; Goodin T; Sharma S; Sanjar S
Int J Chron Obstruct Pulmon Dis; 2021; 16():865-875. PubMed ID: 33833507
[TBL] [Abstract][Full Text] [Related]
4. The Effect of Baseline Rescue Medication Use on Efficacy and Safety of Nebulized Glycopyrrolate Treatment in Patients with COPD from the GOLDEN 3 and 4 Studies.
Donohue JF; Ozol-Godfrey A; Goodin T; Sanjar S
Int J Chron Obstruct Pulmon Dis; 2020; 15():745-754. PubMed ID: 32341641
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of glycopyrrolate/eFlow
Kerwin E; Donohue JF; Goodin T; Tosiello R; Wheeler A; Ferguson GT
Respir Med; 2017 Nov; 132():238-250. PubMed ID: 28838685
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of a novel, nebulized glycopyrrolate for the treatment of COPD: effect of baseline disease severity and age; pooled analysis of GOLDEN 3 and GOLDEN 4.
Ohar J; Tosiello R; Goodin T; Sanjar S
Int J Chron Obstruct Pulmon Dis; 2019; 14():27-37. PubMed ID: 30587959
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of glycopyrrolate in patients with COPD by reversibility: pooled analysis of GEM1 and GEM2 12-week studies.
Ohar JA; Bowling A; Goodin T; Price B; Ozol-Godfrey A; Sharma S; Sanjar S
Int J Chron Obstruct Pulmon Dis; 2019; 14():461-470. PubMed ID: 30863047
[TBL] [Abstract][Full Text] [Related]
8. Impact of Comorbidity Prevalence and Cardiovascular Disease Status on the Efficacy and Safety of Nebulized Glycopyrrolate in Patients with COPD.
Putcha N; Ozol-Godfrey A; Sanjar S; Sharma S
Int J Chron Obstruct Pulmon Dis; 2021; 16():1061-1073. PubMed ID: 33907393
[TBL] [Abstract][Full Text] [Related]
9. Clinically Important Deterioration Among Patients with Chronic Obstructive Pulmonary Disease (COPD) Treated with Nebulized Glycopyrrolate: A Post Hoc Analysis of Pooled Data from Two Randomized, Double-Blind, Placebo-Controlled Studies.
Kerwin EM; Murray L; Niu X; Dembek C
Int J Chron Obstruct Pulmon Dis; 2020; 15():2309-2318. PubMed ID: 33061349
[TBL] [Abstract][Full Text] [Related]
10. Effect of background long-acting beta
Kerwin EM; Tosiello R; Price B; Sanjar S; Goodin T
Int J Chron Obstruct Pulmon Dis; 2018; 13():2917-2929. PubMed ID: 30275690
[TBL] [Abstract][Full Text] [Related]
11. Long-term safety of glycopyrrolate/eFlow
Ferguson GT; Goodin T; Tosiello R; Wheeler A; Kerwin E
Respir Med; 2017 Nov; 132():251-260. PubMed ID: 28919143
[TBL] [Abstract][Full Text] [Related]
12. Indacaterol/glycopyrronium versus tiotropium or glycopyrronium in long-acting bronchodilator-naïve COPD patients: A pooled analysis.
Muro S; Yoshisue H; Kostikas K; Olsson P; Gupta P; Wedzicha JA
Respirology; 2020 Apr; 25(4):393-400. PubMed ID: 31339215
[TBL] [Abstract][Full Text] [Related]
13. Reduction in clinically important deterioration in chronic obstructive pulmonary disease with aclidinium/formoterol.
Singh D; D'Urzo AD; Chuecos F; Muñoz A; Garcia Gil E
Respir Res; 2017 May; 18(1):106. PubMed ID: 28558833
[TBL] [Abstract][Full Text] [Related]
14. Dose selection for glycopyrrolate/eFlow
Donohue JF; Goodin T; Tosiello R; Wheeler A
Respir Res; 2017 Dec; 18(1):202. PubMed ID: 29202767
[TBL] [Abstract][Full Text] [Related]
15. Effect of smoking status on lung function, patient-reported outcomes, and safety among COPD patients treated with glycopyrrolate inhalation powder: pooled analysis of GEM1 and GEM2 studies.
Tashkin DP; Goodin T; Bowling A; Price B; Ozol-Godfrey A; Sharma S; Sanjar S
Respir Res; 2019 Jul; 20(1):135. PubMed ID: 31266489
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of twice-daily indacaterol/glycopyrrolate inhalation powder for the treatment of moderate to severe COPD in the US.
Rajagopalan K; Bloudek L; Marvel J; Dembek C; Kavati A
Int J Chron Obstruct Pulmon Dis; 2018; 13():3867-3877. PubMed ID: 30568438
[TBL] [Abstract][Full Text] [Related]
17. Long-term safety of glycopyrrolate: A randomized study in patients with moderate-to-severe COPD (GEM3).
Mahler DA; Gifford AH; Satti A; Jessop N; Eckert JH; D'Andrea P; Mota F; Banerjee R
Respir Med; 2016 Jun; 115():39-45. PubMed ID: 27215502
[TBL] [Abstract][Full Text] [Related]
18. Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial.
Baumgartner RA; Hanania NA; Calhoun WJ; Sahn SA; Sciarappa K; Hanrahan JP
Clin Ther; 2007 Feb; 29(2):261-78. PubMed ID: 17472819
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of Indacaterol/Glycopyrrolate in Patients with COPD by Airway Reversibility at Baseline: A Pooled Analysis of the FLIGHT1 and FLIGHT2 12-Week Studies.
Ohar JA; Sharma S; Goodin T; Bowling A; Price B; Ozol-Godfrey A; Sanjar S
COPD; 2019 Apr; 16(2):133-139. PubMed ID: 31242792
[TBL] [Abstract][Full Text] [Related]
20. Benefits of Tiotropium/Olodaterol Compared with Tiotropium in Patients with COPD Receiving only LAMA at Baseline: Pooled Analysis of the TONADO
Buhl R; Singh D; de la Hoz A; Xue W; Ferguson GT
Adv Ther; 2020 Aug; 37(8):3485-3499. PubMed ID: 32462607
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]